Search research articles
Contact Us
Filters
Showing results (61-70 of 101) with videos related to
Page
of 11
Sort By:
Hepatology International
|
January 10, 2021
Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan
Fu-Shun Yen, James Cheng-Chung Wei, Hei-Tung Yip, et al.
Journal of Personalized Medicine
|
May 28, 2022
Role of Metformin in Morbidity and Mortality Associated with Urinary Tract Infections in Patients with Type 2 Diabetes
Fu-Shun Yen, James Cheng-Chung Wei, Ying-Hsiu Shih, et al.
Frontiers in Immunology
|
May 20, 2022
Association Between Endometriosis and Subsequent Risk of Sjögren's Syndrome: A Nationwide Population-Based Cohort Study
Yung-Hsiang Chao, Chin-Hsiu Liu, Yu-An Pan, et al.
BMC Medicine
|
January 3, 2024
Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes
Fu-Shun Yen, Ming-Chih Hou, James Cheng-Chung Wei, et al.
Diabetes, Obesity & Metabolism
|
August 27, 2025
Impact of glucagon-like peptide-1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
Fu-Shun Yen, Shiow-Ing Wang, Yao-Min Hung, et al.
Diabetes Research and Clinical Practice
|
April 19, 2026
SGLT2 inhibitors and the risk of incident chronic kidney disease in type 2 diabetes: a nationwide emulated target trial in Taiwan
Fu-Shun Yen, James Cheng-Chung Wei, Yao-Min Hung, et al.
Journal of Autoimmunity
|
October 19, 2025
Comparative risk of rheumatoid arthritis between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes
Fu-Shun Yen, Shiow-Ing Wang, Chii-Min Hwu, et al.
Thorax
|
October 1, 2024
Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD
Fu-Shun Yen, Chih-Cheng Hsu, James Cheng-Chung Wei, et al.
British Journal of Clinical Pharmacology
|
July 1, 2021
Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis
Fu-Shun Yen, Yi-Hsiang Huang, Ming-Chih Hou, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 22, 2020
Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes
Fu-Shun Yen, Yu-Cih Yang, Chii-Min Hwu, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 101) with videos related to
Sort By:
Page
of 11
Hepatology International
|
January 10, 2021
Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan
Fu-Shun Yen, James Cheng-Chung Wei, Hei-Tung Yip, et al.
Journal of Personalized Medicine
|
May 28, 2022
Role of Metformin in Morbidity and Mortality Associated with Urinary Tract Infections in Patients with Type 2 Diabetes
Fu-Shun Yen, James Cheng-Chung Wei, Ying-Hsiu Shih, et al.
Frontiers in Immunology
|
May 20, 2022
Association Between Endometriosis and Subsequent Risk of Sjögren's Syndrome: A Nationwide Population-Based Cohort Study
Yung-Hsiang Chao, Chin-Hsiu Liu, Yu-An Pan, et al.
BMC Medicine
|
January 3, 2024
Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes
Fu-Shun Yen, Ming-Chih Hou, James Cheng-Chung Wei, et al.
Diabetes, Obesity & Metabolism
|
August 27, 2025
Impact of glucagon-like peptide-1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
Fu-Shun Yen, Shiow-Ing Wang, Yao-Min Hung, et al.
Diabetes Research and Clinical Practice
|
April 19, 2026
SGLT2 inhibitors and the risk of incident chronic kidney disease in type 2 diabetes: a nationwide emulated target trial in Taiwan
Fu-Shun Yen, James Cheng-Chung Wei, Yao-Min Hung, et al.
Journal of Autoimmunity
|
October 19, 2025
Comparative risk of rheumatoid arthritis between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes
Fu-Shun Yen, Shiow-Ing Wang, Chii-Min Hwu, et al.
Thorax
|
October 1, 2024
Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD
Fu-Shun Yen, Chih-Cheng Hsu, James Cheng-Chung Wei, et al.
British Journal of Clinical Pharmacology
|
July 1, 2021
Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis
Fu-Shun Yen, Yi-Hsiang Huang, Ming-Chih Hou, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 22, 2020
Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes
Fu-Shun Yen, Yu-Cih Yang, Chii-Min Hwu, et al.
Page
of 11